Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK), a subsidiary of China-based Abbisko Cayman Limited (HKEX Stock Code: 2256.HK), announced on Monday that it has completed dosing of the first patient in the Phase one clinical trial in advanced solid tumours for ABSK061, which is claimed to have become the first highly selective FGFR2/3 inhibitor advanced into clinical stage globally.

The clinical trial is named ABSK061-101, NCT05244551 and is a First-in-Human Phase 1 study of the product to evaluate the safety, tolerability, pharmacokinetics in patients with advanced solid tumours, and to determine the Recommended Phase two Dose (RP2D) and assess preliminary anti-tumour activities. Presently, the trial is being carried out in both China and US.

The product is a new orally available, highly potent and selective small molecule FGFR2/3 inhibitor independently discovered and developed by Abbisko Therapeutics with global intellectual property rights.